Repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) might be a promising treatment strategy for depression. As one of the key features of melancholic depression is disturbances in psychomotor activity, we wanted to evaluate whether HF-rTMS treatment could influence psychomotor symptoms. Twenty antidepressant-free unipolar melancholic depressed patients, all at least stage III medication-resistant, were studied. All were treated with 10 sessions of High-Frequency (HF)-rTMS applied to the left dorsolateral prefrontal cortex (DLPFC) under MRI guidance. Forty percent of the patients showed a reduction of at least 50% on their initial 17-item Hamilton Depression Rating Score (HDRS) scale and were defined as clinical responders. Regardless of clinical outcome HF-rTMS treatment resulted in significant decreases on the Depressive Retardation Rating Scale (DRRS) scores. Although this was an open study in a relatively small sample, our results suggest that HF-rTMS might act on the 'psychomotor' level and these findings could add some further information as to why this kind of treatment can be beneficial for severely depressed patients of the melancholic subtype.
Introduction
Currently, the physiological influences and treatment effects of repetitive Transcranial Magnetic Stimulation (rTMS) in psychiatric patients are under investigation (Burt et al., 2002; Hallett, 2007) . However, the underlying neurobiological mechanism as to how this non-invasive technique can alter depressive states remains unclear (Post and Keck, 2001; George et al., 2003) . Recently, Hoeppner and colleagues published an interesting paper examining psychomotor retardation and agitation in combination with infrathreshold highfrequency (HF)-rTMS in a depressed sample (Hoeppner et al., 2010) . Besides a trend in reduction of agitation, they found no significant influence of HF-rTMS on psychomotor symptoms. Although this was a well carried-out sham-controlled HF-rTMS study, some methodological issues and the concomitant pharmacological antidepressant therapy on the start of their HF-rTMS study might have biased the results (Martin et al., 2003) .
In this study, we wanted to investigate whether suprathreshold HF-rTMS treatment affects psychomotor symptoms in a homogeneous sample of unipolar medication-resistant and antidepressant-free depressed patients, all of the melancholic subtype. As psychomotor retardation is one of the key features of this type of depression (Sobin and Sackeim, 1997; Gold and Chrousos, 2002; Pier et al., 2004) , this group should be in particular suitable to evaluate psychomotor changes in rTMS paradigms. Because a higher level of psychomotor retardation has been associated with reduced metabolic activities in the left dorsolateral prefrontal cortex (DLPFC)-suggesting an important role of this cortical area on psychomotor functioning (Schrijvers et al., 2008)-we targeted this prefrontal cortical area under MRI guidance. We expected that psychomotor retardation symptoms only would improve in clinical HF-rTMS responders.
Methods and materials
The study was approved by the ethics committee and all subjects gave written informed consent. Our study group consisted of twenty antidepressant-free unipolar depressed patients of the melancholic subtype (age 47.05 ± 9.20; 13 females), selected by using the MiniInternational Neuropsychiatric Interview (MINI; Sheehan et al., 1998) . All were right-handed and were considered at least stage III treatment resistant, as described by Rush et al (2003) . Exclusion criteria were
